The market for Tecentriq is expected to grow at a CAGR of around 18.5% from 2020 to 2027 and expected to reach the market value of around US$ 3,859 Mn by 2027.
Tecentriq or Atezolizumab is a monoclonal antibody medication that intends to treat non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, urothelial carcinoma, and hepatocellular carcinoma. Atezolizumab medication is sold under the brand name Tecentriq. Tecentriq has led the way like cancer immunotherapy and has designated as first monoclonal antibody targeting Programmed Death Ligand 1 “PD-L1” to be approved by European Medical Agency (EMA) as a treatment for number of cancer types.
Currently, Aetozulizumab is under Phase 3 clinical trials for the treatment of non-small cell lung cancer. The study is an interventional study which was commenced on March 04, 2020, and estimated completion date August 25, 2022. For records, on May 18, 2020, the U.S. FDA approved Aetozulizumab (Tecentriq) as a first line of treatment for adult’s patients suffering from metastatic non-small cell lung cancer (NSCLC).
Non-approval of Aetozulizumab for the treatment of breast cancer
On September 08, 2020, FDA issued alert about the efficacy and potential safety concerns regarding Aetozulizumab in combination with Paclitaxel utilized for the treatment of breast cancer. The FDA stated that the drug combination did not prove effective in treatment of the disease; therefore, revoking Aetozulizumab in combination with Paclitaxel for the treatment of breast cancer. On the other hand, Aetozulizumab in combination Paclitaxel protein-bound (Abraxane) intends as a different combination therapy that got approval for the breast cancer.
High prevalence of breast cancer, lung cancer, renal cancer, and other tumor related disorders among the population drives the growth of Tecentriq market. In addition, high focus upon the R&D investments by the pharmaceutical companies and government organizations fuels the market growth.
As per the National Cancer Institute, in 2020 an estimated 1,806,590 new cases of cancer were diagnosed in the United States. The most common cancers are breast cancers, lung cancer, renal, and liver cancer. Among these prostates, lung, and colorectal cancer, accounted around 43% of all cancers diagnosed in men for the same year. Moreover, national expenditures coupled with cancer prevelance have been rising steadily in the US. As per the reports by National Cancer Institute, fund available to NCI accounted for USD 5.94 billion post-interdepartmental and intra-NIH transfers. This is reflected by rise in 5% and USD 284 million as compared to previous fiscal year. Further, a Century Cures Act that was signed into law in December 2016 authorized to USD 1.8 billion to fund the Cancer Moonshoot over a 7 years period. Cancer Moonshoot funding received during 2018 ws valued at USD 300 million.
In addition, as per the statistics released by Association for Clinical Oncology for the period of 2013-2019, funding for the National Cancer Institute (NCI) increased by 20% during the same period coupled with grants application rising by 50%. Further, ASCOs found that 73% of Americans depend on government spending more on finding treatment and cures for cancer. Further, possible adverse effects by drug causing agents and high treatment cost restrain the market to grow.
The tecentriq market is segmented based on application and region. On the basis of application, it is segmented as lung cancer, triple-negative breast cancer, small cell lung cancer, urothelial carcinoma, and hepatocellular carcinoma.
Based on application, triple-negative breast cancer will gain a significant growth in the forthcoming years. This is due to high focus upon the research and development activities for innovative technologies. Currently, Nanotechnology has evolved as an efficient tool in the clinical management for triple-negative breast cancer. In addition, new product development and launching by the top pharmaceutical companies will further spur the segmental growth.
For instance, on July 30, 2020, Merck announced that the USFDA has given approval for two new supplemental Biologic Licence Applications namely “KEYTRUDA” and Merck’s “Anti PD-1 therapy” for locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.
Based on the regions, the regional market is segmented as Europe, North America, the Middle East & Africa, Latin America, and Asia Pacific.
Based on the regions, Europe incorporated a strong foothold for tecentriq in the regional market worldwide followed by North America. This is due to flexible grants obtained by the European Commission for the treatment of various forms of cancer. For instance, on September 06, 2019, European Commission approved Roche’s new Tecentriq based combination therapy for initial treatment of most common form of advanced lung cancer. The approval of new Tecentriq based combination offers various treatment options for the population across Europe that are affected by non-squamous non-small cell lung cancer (NSCLC). Furthermore, Roche stated that the European Commission has granted marketing authorization for Tecentriq (Aetozulizumab) in combination of chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]), as the first line of treatment for adults with NSCLC.
North America regional market for Tecentriq is projected to exhibit faster pace in the coming years owing to high R&D activities, prevalence of cancer cases among the population, and government support for funding and treatment.
Global Tecentriq Market Revenue (US$ Mn)
According to Roche, it has witnessed the better success of Tecentriq during its fourth-quarter earnings as on February 2017. As per the Roche, the drug already possesses 60% share of the market that has not observed in decades related to a new treatment that bought CHF 157m (USD158 Million) sales for 2016.
On July 30, 2020-the Food and Drug Administration (FDA) approved Aetozulizumab in combination with Cobimetinib and Vemurafenib for patients suffering from BRAF V600 metastatic melanoma.
For instance, On June 02, 2020- FDA approves Roches’s Tecentriq in combination with Avastin for the patients suffering from liver cancer.
As per the reports published by Roche on October 15, 2020, Pharmaceutical division sales decreased by 1% nearly that involves Tecentriq. This is observed due to COVID-19 pandemic.
The players profiled in the report include Roche, Genentech, Merck & Co. Inc., Cipla, Bristol-Myers Squibb Co., and among others.
Market By Application
Triple-negative breast cancer
Small cell lung cancer
Market By Geography
Middle East & Africa
The market for Tecentriq is expected to reach a market value of around US$ 3,859 Mn by 2027.
The Tecentriq market is expected to grow at a CAGR of around 18.5% from 2020 to 2027.
Triple negative breast cancer is the leading segment in the overall market
Prevalence of breast cancer, renal cancer, lung cancer, and other tumor related disorders across the population drives the tecentriq market. In addition, high focus upon the research and development (R&D) activities, huge investments by pharmaceutical companies, and high government support further bolster the growth of tecentriq market.
Roche, Genentech, Merck & Co. Inc., Cipla, Bristol-Myers Squibb Co., and others.
Europe is anticipated to grab the highest market share in the regional market
North America is expected to be the fastest growing market in the forthcoming years